Literature DB >> 657453

Suppression of calcific fibrous-fatty plaque formation in rabbits by agents not affecting elevated serum cholesterol levels. The effect of thiophene compounds.

C T Chan, H Wells, D M Kramsch.   

Abstract

We tested the suppressive effect of antihypercalcemic-hyperphosphatemic agents on atherogenesis. We studied five groups of rabbits for 8 weeks, one control group and four groups on a fibrogenic atherogenic diet. One group received the atherogenic diet alone, and the remaining three atherogenic groups were treated simultaneously with 2-thiophenecarboxylic acid (ThCA), 5-methyl-2-thiophenecarboxylic acid (5-CH3-ThCA), and 5-bromo-2-thiophenecarboxaldehyde (5-Br-ThCA). Rabbits receiving the atherogenic diet alone developed: (1) elevations of serum cholesterol, calcium, and phosphorus; (2) massive fibrous-fatty aortic plaques with excessive accumulation of aortic collagen, elastin, and lipids; (3) marked deposition of calcium and phosphorus in both aortic tissue and elastin; and (4) severe lipid infiltration of the liver. Treatment with all three drugs normalized the elevated serum calcium but not the cholesterol levels, and effectively inhibited all aspects of the atherosclerotic process as determined morphologically and biochemically. The order of effectiveness was: 5-CH3-ThCa greater than 5-Br-ThCA greater than ThCA. No bone resorption occurred in the treated groups. The normalizing effects of the thiophene compounds on serum phosphorus levels were not significant at the dosages used.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 657453     DOI: 10.1161/01.res.43.1.115

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  13 in total

Review 1.  Influence of nifedipine on experimental arteriosclerosis.

Authors:  A M Knorr; S Kazda
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

2.  Nifedipine and experimental cardioprotection.

Authors:  W G Nayler; J J Liu; S Panagiotopoulos
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

3.  Effects of diltiazem on suppression and regression of experimental atherosclerosis.

Authors:  M Sugano; Y Nakashima; H Tasaki; M Takasugi; A Kuroiwa; O Koide
Journal:  Br J Exp Pathol       Date:  1988-08

4.  Investigation of gender heterogeneity in the associations of serum phosphorus with incident coronary artery disease and all-cause mortality.

Authors:  Stephen J Onufrak; Antonio Bellasi; Francesca Cardarelli; Viola Vaccarino; Paul Muntner; Leslee J Shaw; Paolo Raggi
Journal:  Am J Epidemiol       Date:  2008-11-02       Impact factor: 4.897

5.  Supersensitivity of atherosclerotic rabbit aorta to ergonovine. Mediation by a serotonergic mechanism.

Authors:  P D Henry; M Yokoyama
Journal:  J Clin Invest       Date:  1980-08       Impact factor: 14.808

6.  Isradipine improves platelet function in hypertensives.

Authors:  H Sinzinger; I Virgolini; F Rauscha; P Fitscha; J O'Grady
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

7.  Cholesterol enrichment increases basal and agonist-stimulated calcium influx in rat vascular smooth muscle cells.

Authors:  R A Bialecki; T N Tulenko; W S Colucci
Journal:  J Clin Invest       Date:  1991-12       Impact factor: 14.808

8.  Effects of vasoactive stimuli on coronary vascular resistance in isolated perfused rabbit hearts: no vasospastic response to ergonovine with or without atherogenic diet.

Authors:  T von Arnim; F Crea; S Chierchia; G R Thompson; A Maseri
Journal:  Basic Res Cardiol       Date:  1983 Jul-Aug       Impact factor: 17.165

9.  Suppression of experimental atherosclerosis by the Ca++-antagonist lanthanum. Possible role of calcium in atherogenesis.

Authors:  D M Kramsch; A J Aspen; C S Apstein
Journal:  J Clin Invest       Date:  1980-05       Impact factor: 14.808

10.  Suppression of atherogenesis in cholesterol-fed rabbit treated with nifedipine.

Authors:  P D Henry; K I Bentley
Journal:  J Clin Invest       Date:  1981-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.